

AusCann Group Holdings Ltd

21:12 16 Dec 2018

AusCann Group shortlists candidates for chief executive officer role

AusCann Group Holdings Ltd's (ASX:AC8) search for a new chief executive officer is progressing to plan and is now at an advanced stage.

The board has selected a final shortlist and is confident in the high calibre of Australian and international candidates that it believes have the necessary skills and experience to guide AusCann through its next phase of growth as a pharmaceutical manufacturing and sales business.

AusCann is expected to make an appointment once final interviews have been completed early in the new year.

Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board.

READ: AusCann Group appoints Paul MacLeman as executive director

Dr MacLeman is an experienced pharmaceutical executive and has been a senior consultant to AusCann since October 2017. He is leading the board's executive CEO search process.

AusCann managing director Elaine Darby said: "The CEO search process is progressing very well and is now nearing completion.

"The transition is a natural evolution that reflects the continued growth and development of AusCann, and the board has worked to ensure it is a well planned and orderly one.

READ: AusCann Group appoints PCI Pharma to manufacture first product line

"I am extremely proud of what we have achieved at AusCann since the inception of the company in 2014 and listing in early 2017, including our licensing, cultivation, and product development activities which have culminated into our hard shell capsules soon to be commercialised.

"I am confident AusCann will go from strength to strength as it moves into a manufacturing and marketing footing for our first-generation product range.

"We see innovation and continued new product development as key to the next stages of the company's development."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

Price: A\$0.38

Market Cap: A\$117.49M

1 Year Share Price Graph



May 2018 November 2018 May 2019

Share Information

Code: AC8

Listing: ASX

52 week **High** **Low**
A\$1.50 A\$0.30

Sector: Cannabis

Website: www.auscann.com.au

Company Synopsis:

AusCann Group Holdings Ltd (ASX:AC8) is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products. We are an Australian based company and our aim is to produce and provide high quality, economical and clinically validated cannabis medicines to Australian patients.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.